Dimerix (CHIA:DXB) - Stock Price, News & Analysis

DXB Stock Overview

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. More details

DXB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 29.5% per year over past 5 years

Makes less than USD$1m in revenue (A$583K)

Shareholders have been diluted in the past year

Dimerix Limited Competitors

Imugene

ASX:IMU

AU$275.2m

Immutep

ASX:IMM

AU$414.6m

Aroa Biosurgery

ASX:ARX

AU$224.2m

Beroni Group

NSX:BTG

AU$75.9m

Price History & Performance

Summary of all time highs, changes and price drops for Dimerix
Historical stock prices
Current Share Price	AU$0.33
52 Week High	AU$0.67
52 Week Low	AU$0.13
Beta	0.50
11 Month Change	-26.67%
3 Month Change	-24.14%
1 Year Change	140.00%
33 Year Change	37.50%
5 Year Change	164.00%
Change since IPO	175.00%

Recent updates

Shareholder Returns

	DXB	AU Biotechs	AU Market
7D	-12.0%	-3.8%	0.9%
1Y	140.0%	9.9%	17.7%

Return vs Industry: DXB exceeded the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: DXB exceeded the Australian Market which returned 17.2% over the past year.

Price Volatility

Is DXB's price volatile compared to industry and market?
DXB volatility
DXB Average Weekly Movement	8.5%
Biotechs Industry Average Movement	9.9%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.3%

Stable Share Price: DXB has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: DXB's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Nina Webster	dimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

Dimerix Limited Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
DXB fundamental statistics
Market cap	AU$181.07m
Earnings (TTM)	-AU$17.08m
Revenue (TTM)	AU$583.48k

310.3x

P/S Ratio

-10.6x

P/E Ratio

Is DXB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXB income statement (TTM)
Revenue	AU$583.48k
Cost of Revenue	AU$0
Gross Profit	AU$583.48k
Other Expenses	AU$17.66m
Earnings	-AU$17.08m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.031
Gross Margin	100.00%
Net Profit Margin	-2,926.43%
Debt/Equity Ratio	0%

How did DXB perform over the long term?

See historical performance and comparison

DXB Stock Overview

Risk Analysis

Dimerix Limited Competitors

ASX:IMU

AU$275.2m

ASX:IMM

AU$414.6m

ASX:ARX

AU$224.2m

NSX:BTG

AU$75.9m

Price History & Performance

Recent News & Updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

New major risk - Revenue size

Dimerix Limited, Annual General Meeting, Oct 01, 2024

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Recent updates

Dimerix Limited Appoints Laura Mariani to Medical Advisory Board

New major risk - Revenue size

Dimerix Limited, Annual General Meeting, Oct 01, 2024

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.21

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.45

Shareholder Returns

Price Volatility

About the Company

Dimerix Limited Fundamentals Summary

310.3x

-10.6x

Earnings & Revenue